메뉴 건너뛰기




Volumn 172, Issue 2, 2014, Pages 469-470

Outcomes with short-term versus long-term antiplatelet dual therapy after drug-eluting stenting: Quantifying the equivalence margins

Author keywords

Antiplatelet; Dual therapy; Equivalence; Meta analysis; Stenting

Indexed keywords

ANTICOAGULANT THERAPY; ANTIPLATELET DUAL THERAPY; ATTRIBUTABLE RISK; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; DRUG ELUTING STENT; DRUG SAFETY; DRUG USE; HUMAN; LETTER; LONG TERM CARE; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SHORT COURSE THERAPY; THERAPEUTIC EQUIVALENCE; TREATMENT DURATION; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION; META ANALYSIS; TREATMENT OUTCOME;

EID: 84900107208     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.12.228     Document Type: Article
Times cited : (7)

References (7)
  • 1
    • 84885621077 scopus 로고    scopus 로고
    • Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: A meta-analysis of randomized trials
    • M. Valgimigli, S.J. Park, and H.S. Kim et al. Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials Int J Cardiol 168 3 Oct 3 2013 2579 2587
    • (2013) Int J Cardiol , vol.168 , Issue.3 , pp. 2579-2587
    • Valgimigli, M.1    Park, S.J.2    Kim, H.S.3
  • 2
    • 84877866855 scopus 로고    scopus 로고
    • Optimal duration of dual-antiplatelet therapy following drug-eluting stent implantation: A meta-analysis
    • T. Zhang, L. Shen, L. Hu, and B. He Optimal duration of dual-antiplatelet therapy following drug-eluting stent implantation: a meta-analysis J Clin Pharmacol 53 3 Mar 2013 345 351
    • (2013) J Clin Pharmacol , vol.53 , Issue.3 , pp. 345-351
    • Zhang, T.1    Shen, L.2    Hu, L.3    He, B.4
  • 3
    • 84867050148 scopus 로고    scopus 로고
    • A new strategy for discontinuation of dual antiplatelet therapy: The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)
    • B.K. Kim, M.K. Hong, and D.H. Shin et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) J Am Coll Cardiol 60 15 Oct 9 2012 1340 1348
    • (2012) J Am Coll Cardiol , vol.60 , Issue.15 , pp. 1340-1348
    • Kim, B.K.1    Hong, M.K.2    Shin, D.H.3
  • 4
    • 84890373385 scopus 로고    scopus 로고
    • Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The OPTIMIZE randomized trial
    • F. Feres, R.A. Costa, and A. Abizaid et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial JAMA 310 23 2013 2510 2522
    • (2013) JAMA , vol.310 , Issue.23 , pp. 2510-2522
    • Feres, F.1    Costa, R.A.2    Abizaid, A.3
  • 5
    • 84874928691 scopus 로고    scopus 로고
    • No evidence of efficacy or evidence of no efficacy
    • M.A. Arruda No evidence of efficacy or evidence of no efficacy JAMA Pediatr 167 3 2013 300 302
    • (2013) JAMA Pediatr , vol.167 , Issue.3 , pp. 300-302
    • Arruda, M.A.1
  • 6
    • 84876892984 scopus 로고    scopus 로고
    • How to demonstrate similarity by using noninferiority and equivalence statistical testing in radiology research
    • S. Ahn, S.H. Park, and K.H. Lee How to demonstrate similarity by using noninferiority and equivalence statistical testing in radiology research Radiology 267 2 2013 328 338
    • (2013) Radiology , vol.267 , Issue.2 , pp. 328-338
    • Ahn, S.1    Park, S.H.2    Lee, K.H.3
  • 7
    • 84976899255 scopus 로고    scopus 로고
    • High-titre inhibitors in previously untreated patients with severe hemophilia A: An updated estimate of pooled incidence rates in patients treated with plasma-derived concentrates or recombinant Factor VIII
    • A. Messori, V. Fadda, D. Maratea, S. Trippoli, and C. Marinai High-titre inhibitors in previously untreated patients with severe hemophilia A: an updated estimate of pooled incidence rates in patients treated with plasma-derived concentrates or recombinant Factor VIII Drugs and Cell Therapy in Hematology 2 3 2013 224 235
    • (2013) Drugs and Cell Therapy in Hematology , vol.2 , Issue.3 , pp. 224-235
    • Messori, A.1    Fadda, V.2    Maratea, D.3    Trippoli, S.4    Marinai, C.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.